UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-QSB
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: July 31, 2004
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to __________
Commission File Number: 333-103083
XENOMICS, INC.
-----------------------------------------------------
(Exact name of Registrant as specified in its charter)
Florida 04-3721895
------------------------------- --------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
420 Lexington Avenue, Suite 1701, New York, New York 10170
----------------------------------------------------------
(Address of principal executive offices) (Zip Code)
(732) 438-8290
-------------------------------
(Registrant's telephone number)
----------------------------------------------------
(Former Name, Former Address and Former Fiscal Year,
if changed since last report)
Check whether the issuer: (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and
(2) has been subject to such filing requirements for past 90 days.
[X] Yes [ ] No
APPLICABLE ONLY TO CORPORATE ISSUERS:
State the number of shares outstanding of each of the issuer's classes
of common equity, as of the latest practicable date:
Class Outstanding at September 17, 2004
Common Stock, par value $0.0001 15,588,737 shares
Transitional Small Business Disclosure Format (check one): Yes [ ] No [X]
XENOMICS, INC.
FORM 10-QSB
CONTENTS
PART I -- FINANCIAL INFORMATION Page
Item 1. Condensed Consolidated Financial Statements
Unaudited Condensed Consolidated Balance Sheet as
of July 31, 2004 1
Unaudited Condensed Consolidated Statements of
Operations for the Three and Six Months Ended
July 31, 2004 and 2003 and the period
April 26, 2002 (Inception) to July 31, 2004 2
Unaudited Condensed Consolidated Statements of Cash
Flows for the Six Months Ended July 31, 2004 and
2003 and for the period April 26, 2002 (Inception)
to July 31, 2004 3
Notes to Unaudited Condensed Consolidated Financial
Statements 4
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations 8
Item 3. Controls and Procedures 10
PART II -- OTHER INFORMATION
Item 2. Changes in Securities and Use of Proceeds 11
Item 6. Exhibits and Reports on Form 8-K 12
Signatures 13
i
INTRODUCTORY NOTE
This Report on Form 10-QSB for Xenomics, Inc. (the "Company") may contain
forward-looking statements. You can identify these statements by forward-looking
words such as "may," "will," "expect," "intend," "anticipate," believe,"
"estimate" and "continue" or similar words. Forward-looking statements include
information concerning possible or assumed future business success or financial
results. You should read statements that contain these words carefully because
they discuss future expectations and plans, which contain projections of future
results of operations or financial condition or state other forward-looking
information. We believe that it is important to communicate future expectations
to investors. However, there may be events in the future that we are not able to
accurately predict or control. Accordingly, we do not undertake any obligation
to update any forward-looking statements for any reason, even if new information
becomes available or other events occur in the future.
The forward-looking statements included herein are based on current expectations
that involve a number of risks and uncertainties set forth under "Risk Factors"
in our report on Form 8-K and other periodic reports filed with the SEC.
Accordingly, to the extent that this Report contains forward-looking statements
regarding the acquisitions, financial condition, operating results, business
prospects or any other aspect of the Company, please be advised that the
Company's actual financial condition, operating results and business performance
may differ materially from that projected or estimated by the Company in
forward-looking statements. Unless otherwise indicated in this Report all share
and per share information gives effect to a 111 for 1 stock split effected on
July 26, 2004.
ii
PART I - FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements
Xenomics, Inc.
(A Development Stage Company)
Consolidated Balance Sheet
July 31, 2004
(Unaudited)
ASSETS
CURRENT ASSETS
Cash $ 1,505,095
Prepaid expenses 16,490
--------------
Total current assets 1,521,585
--------------
FIXED ASSETS 41,137
--------------
OTHER ASSETS
Patents 38,732
Security deposits 50,617
--------------
Total other assets 89,349
--------------
Total Assets $ 1,652,071
==============
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
CURRENT LIABILITIES
Accounts payable and accruals $ 33,892
--------------
Total current liabilities 33,892
--------------
Total Liabilities 33,892
--------------
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, $.001 par value, 20,000,000 shares
authorized, none outstanding -
Common stock, $0.0001 par value, 100,000,000 shares
authorized; 15,938,737 issued and outstanding 1,594
Treasury Stock- 350,000 shares (35)
Additional paid in capital 1,717,587
Accumulated (Deficit) during development stage (100,967)
--------------
Total Stockholders' Equity 1,618,179
--------------
Total Liabilities and Stockholders' Equity $ 1,652,071
==============
The accompanying notes are an integral part of the financial statements
1
Xenomics, Inc.
(A Development Stage Company)
Consolidated Statements of Operations
For the Six Months and Three Months Ending July 31, 2004 and for the Period
Commencing April 26, 2002 (Date of inception) to July 31, 2004 (Unaudited)
Cumulative
From For Six For Six For Three For Three
April 26, 2002 Months Months Months Months
(inception) Ended Ended Ended Ended
Through July 31 July 31 July 31 July 31
July 31, 2004 2004 2003 2004 2003
---------------- ----------------------------- ------------------------------
Revenues $ 0 $ 0 $ 0 $ 0 $ 0
Operating expenses 100,967 95,773 424 92,953 559
---------------- ----------------------------- ------------------------------
Net income (loss) before provision
for income taxes (100,967) (95,773) (424) (92,953) (559)
---------------- ----------------------------- ------------------------------
Provision for income taxes 0 0 0 0 0
-----------------------------------------------------------------------------
Net income (loss) $(100,967) $ (95,773) $ (424) $ (92,953) $ (559)
================ ============================= ==============================
Weighted average shares outstanding 221,906,598 229,548,000 208,152,074 229,548,000
============================================================
Net Income (Loss) - per share,
Basic and diluted $ (0.00) $ (0.00) $ (0.00) $ (0.00)
============================================================
The accompanying notes are an integral part of the financial statements
2
Xenomics, Inc.
(A Development Stage Company)
Consolidated Statements of Cash Flows
For the Six Months Ending July 31, 2004 and for the Period Commencing April 26,
2002 (Date of inception) to July 31, 2004 (Unaudited)
Cumulative
From For the For the
April 26, 2002 Six Months Six Months
(inception) Ended Ended
Through July 31 July 31
July 31, 2004 2004 2003
------------------ --------------- -----------------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) $ (100,967) $ (95,773) $ (424)
Adjustments to reconcile net income (loss) to net cash
used for operations:
Change in operating assets and liabilities:
(Increase) in prepaid expenses (16,490) (16,490) 0
Increase (Decrease) in accounts payable & accruals 33,892 (8,205) 365
------------ ------------ ------------
Net cash used by operating activities (83,565) (120,468) (59)
------------ ------------ ------------
CASH FLOW FROM INVESTING ACTIVITIES:
(Increase) in security deposits (50,617) (50,617) 0
Purchase of fixed assets (41,137) (41,137) 0
Patent Costs (38,732) (1,732) 0
------------ ------------ ------------
Net cash (used) by investing activities (130,486) (93,486) 0
------------ ------------ ------------
CASH FLOW FROM FINANCING ACTIVITIES:
Net Proceeds from private placement 2,368,510 2,368,510 0
Payment of acquisition costs (149,800) (149,800) 0
Purchase of common stock (500,000) (500,000) 0
------------ ------------ ------------
Net cash provided by financing activities 1,718,710 1,718,710 0
------------ ------------ ------------
Net Increase (Decrease) in cash 1,504,659 1,504,756 (59)
CASH, beginning of period, 436 339 495
------------ ------------ ------------
CASH, end of period $ 1,505,095 $ 1,505,095 $ 436
============ ============ ============
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for Interest Expenses $ 0 $ 0 $ 0
Cash paid for Income Taxes $ 0 $ 0 $ 0
The accompanying notes are an integral part of the financial statements
3
Xenomics, Inc.
(A Development Stage Company)
Notes to Consolidated Financial Statements
NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Organization
------------
The Company was organized under the laws of the State of Florida on April 26,
2002 as Used Kar Parts Inc. On July 2, 2004, following the acquisition of 100%
of the outstanding stock of Xenomics (a California corporation) which is treated
as reverse acquisition for accounting purposes, the Company changed its name to
Xenomics, Inc. The Company is in the development stage and plans to generate
revenue from developing its medical patents. Currently the Company has no
revenue..
Basis of Accounting
-------------------
The Company's policy is to prepare its financial statements using the accrual
basis of accounting in accordance with generally accepted accounting principles.
The Company has elected to use January 31 as its annual year end.
Use of Estimates
----------------
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reporting period.
Actual results could differ from those estimates.
Cash Equivalents
----------------
For purposes of the statement of cash flows, the Company treats all short-term
investments with maturities of six months or less to be cash equivalents.
Development Stage Company
-------------------------
The Company has been in the development stage since inception (April 26, 2002).
There have been no revenues to date. The Company has incurred an accumulated
deficit of approximately $100,967 since inception.
Concentration of Risk
---------------------
The Company places its cash in high credit quality financial institutions. For
the period ending July 31, 2004 the Company had on deposit funds in excess of
the $100,000 FDIC insured limits. Management does not believe that there is any
concentration risk.
4
Xenomics, Inc.
(A Development Stage Company)
Notes to Consolidated Financial Statements
Income Taxes
------------
The Company accounts for income taxes under the accrual method established by
Statement of Financial Accounting Standards (SFAS) No. 109, which requires
recognition of deferred tax assets and liabilities for the expected future tax
consequences and events that have been included in the financial statements or
tax returns. Under this method, deferred tax assets and liabilities are
determined based on assets and liabilities using enacted rates for the year in
which the differences are expected to reverse.
Principles of Consolidation
---------------------------
The consolidated financial statements include the accounts of Xenomics, Inc. and
its wholly-owned subsidiary Xenomics. All intercompany transactions have been
eliminated.
Net Loss Per Share, basic
-------------------------
Net income (loss) per share is computed by dividing the net income (loss) by the
weighted average number of shares outstanding during the period. Net income
(loss) per share, diluted, is not presented due to the anti-dilutive nature of
the securities outstanding.
Fair value of financial instruments
-----------------------------------
The following methods and assumptions were used to estimate the fair value of
each class of financial instruments: cash, and accounts payable. The carrying
amounts approximated fair value because of the demand nature of these
instruments.
Interim Statements
------------------
The financial statements for the six and three months ending July 31, 2004 and
2003 are unaudited and include all adjustments which in the opinion of
management are necessary for a fair presentation, and such adjustments are of a
normal and recurring nature. The results of operations for the six and three
months are not indicative of a full year results.
NOTE 2 CAPITAL STOCK TRANSACTIONS
Pursuant to a private placement on July 2, 2004, the Company sold 2,645,210
shares of common stock for $2,512,859. The Company purchased from former
shareholders 1,971,734 post-split shares of common stock for $500,000 on July 2,
2004. On July 2, 2004, the Company acquired all of the shares of common stock of
Xenomics (a California corporation) for 2,258,001 shares of common stock
As part of the Xenomics acquisition, 350,000 shares of common stock issued in
the name of the Company and subject to release or cancellation under an escrow
agreement to cover undisclosed liabilities, if any, are carried as treasury
shares..
Effective July 26, 2004, the Company had a 111 to 1 forward stock split. All
financial and per share data has been adjusted accordingly.
As of July 31, 2004, the Company had issued 20,000 stock warrants for services,
at an exercise price of $1.25, immediately vesting and expiring July 23, 2009.
5
Xenomics, Inc.
(A Development Stage Company)
Notes to Consolidated Financial Statements
NOTE 3 INCOME TAXES
In February 1992, the Financial Standards Board issued Statement of Financial
Accounting Standards No. 109, Accounting for Income Taxes. Under SFAS No. 109,
deferred assets and liabilities are recognized for the estimated future tax
consequences between the financial statement carrying amounts of the existing
assets and their respective basis.
Deferred assets and liabilities are measured using enacted tax rates in effect
for the year in which temporary differences are expected to be recovered or
settled. Under SFAS No. 109 the effect on deferred assets and liabilities of a
change in tax rates is recognized in the period that includes the enactment
date.
The Company has a net operating loss carry forward of approximately $5,000 which
is offset by a 100% valuation allowance due to the uncertainty surrounding the
ultimate realization of these assets. The loss carry-forward expires in 15
years.
NOTE 4 PATENT EXPENSES
As of July 31, 2004, the Company has capitalized costs related to patent
development of $38,732. Patents generally have a life of seventeen years.
Additional patent development is to be continued, and as of yet no revenues have
been generated under these patents.
NOTE 5 CONTRACTS AND COMMITTMENTS
Pursuant to a royalty agreement dated December 21, 1999, the Company is
obligated to pay $5,000 annually commencing May 17, 2000 as consideration for
the assignment of intellectual property to the Company. On July 2, 2004 all
royalties incurred as of that date ($25,000) were paid.
Commencing in July 2004, the Company has entered into three year employment
agreements with three key executives for a combined annual compensation of
$375,000 (increasing to $485,000 upon the occurrence of certain events).
Additionally, the individuals were granted stock options of 3,037,500 shares of
common stock at $1.25 per share vesting progressively after 1 year of
employment.
NOTE 6 FIXED ASSETS
The cost of property and equipment will be depreciated using the straight-line
methods over their estimated useful lives (5-7 years). The Company acquired
laboratory equipment for $41,137 in July 2004 and will commence depreciation
upon installation and usage.
NOTE 7 LEASE COMMITTMENTS
Office Facilities
-----------------
The Company executed a lease agreement commencing September 15, 2004 and
expiring September 30, 2011. Annual base rent for the year ending September 2005
is $71,649 increasing to an annual base rent ending on September 30, 2011 of
$80,689.
Laboratory Facilities
---------------------
The Company executed a lease agreement commencing September 1, 2004 and expiring
in August 2006. The total monthly rent (inclusive of common area and maintenance
charges) is $10,028. For the years ending January 31, 2004, 2005 and 2006, the
lease liability is $50,140, $120,336 and $70,196, respectively.
NOTE 8 STOCK OPTION PLAN
The Company has reserved 5,000,000 shares of common stock for issuance upon
exercise of options grants under the 2004 Stock Option Plan, instituted in June
2004. As of July 31 2004, 4,087,500 of options have been granted at a conversion
price of $1.25 per share, and would be fully vested after three years. The
options expire after ten years in 2014.
The Company has not recognized an expense for these options due to the limited
market for the Company's common stock.
NOTE 9 INVESTMENT IN SUBSIDIARY
The Company's Xenomics subsidiary formed SpaXen Italia SRL (an Italian limited
liability company), owned 50/50 with an unaffiliated entitnty and entered into a
shareholder's agreement on April 7, 2004. Xenomics' contribution for its 50%
interest in SpaXen consists of rights in a certain technology and related patent
application that applies Xenomics' technology in the field of infectious
diseases. The other 50% partner will contribute to the subsidiary 100,000 Euros
as working capital. SpaXen had minimal activity.
6
Xenomics, Inc.
(A Development Stage Company)
Notes to Consolidated Financial Statements
NOTE 10 NEW ACCOUNTING PRONOUNCEMENTS
In December 2002, the FASB issued Statement of Financial Accounting Standards
No. 148, Accounting for Stock-Based Compensation - Transition and Disclosure, an
Amendment of FASB Statement No. 123 (SFAS 148). SFAS 148 amends SFAS 123
Accounting for Stock-Based Compensation, providing for an alternative method of
transition for a voluntary change to the fair value based method of accounting
for stock-based employee compensation. Additionally, it amends the disclosure
requirements of SFAS 123 to require prominent disclosures in both annual and
interim financial statements about the method of accounting for stock-based
employee compensation and the effect of the method used on reported results.
SFAS 148 is effective for fiscal years beginning after December 15, 2002. The
interim disclosure provisions are effective for financial reports containing
financial statements for interim periods beginning after December 15, 2002. The
Company's adoption of the interim disclosure provisions of SFAS 148 did not
affect our financial position.
In May 2003, the FASB issued Statement of Financial Accounting Standards No.
150, Accounting for Certain Financial Instruments with Characteristics of both
Liabilities and Equity (SFAS 150). SFAS 150 sets standards for an issuer as to
how to classify and measure financial instruments with characteristics of both
liabilities and equity. SFAS 150 is effective for financial instruments entered
into after May 31, 2003, and is effective after June 15, 2003. Adoption of SFAS
150 is not expected to have a material effect on the Company.
7
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations
The following discussion should be read in conjunction with our condensed
consolidated financial statements and notes to those statements. In addition to
historical information, the following discussion and other parts of this
quarterly report contain forward-looking information that involves risks and
uncertainties.
Overview
--------
We were incorporated in the State of Florida on April 26, 2002 and planned to
develop an on-line marketplace for used car parts. In an effort to develop that
business, we entered into a contract with a web hosting service on a month to
month basis to provide storage for website development and transaction
processing. Our temporary website arrangement was suspended to preserve cash and
pending new management's evaluation of the business.
We acquired Xenomics, a California corporation, on July 2, 2004. Xenomics is a
biotechnology company that focuses on the development of diagnostic tests
utilizing transrenal nucleic acids (Tr-NA) for a broad range of diagnostic
tests. Tr-NA's are components of DNA derived from the blood stream that have
been shown to cross the kidney barrier and can be detected in urine. Xenomics is
a California corporation that was organized in 1999. In March 2004, Xenomics
organized a joint venture with the Spallanzani National Institute for Infectious
Diseases (Instituto Nazionale per le Malattie Infettive, "INMI") in Rome, Italy,
in the form of a new R&D company called SpaXen Italia, S.R.L ("SpaXen") which
will conduct research and development on non-invasive diagnostic tests for
infectious disease using Tr-NA methodology.
We are a development stage medical diagnostic company. Since inception on April
26, 2002 through July 31, 2004, we have sustained cumulative net losses of
$100,967. Our losses have resulted primarily from research and development
expenses, patent costs and legal and accounting expenses. From inception through
July 31, 2004, we have not generated any revenue from operations. We expect to
incur additional losses to perform further research and development activities.
History
-------
We completed the acquisition of Xenomics, an unaffiliated California corporation
on July 2, 2004 by issuing 2,258,001 shares of our common stock to Xenomics'
five shareholders in exchange for all outstanding shares of Xenomics stock (the
"Exchange"). The Exchange was made according to the terms of a Securities
Exchange Agreement dated May 18, 2004. As part of the Exchange, we:
o redeemed 1,971,734 pre-split shares (the equivalent of
218,862,474 post-split shares) from Panetta Partners Ltd., a
principal shareholder, for $500,000 or $0.0023 per share.
o amended our articles of incorporation to change our corporate
name to "Xenomics, Inc." and to split our stock outstanding
prior to the redemption 111 for 1 (effective July 26, 2004).
o entered into employment agreements with two of the former
Xenomics shareholders and a consulting agreement with one of
the former Xenomics shareholders.
o entered into a Voting Agreement with the certain investors,
the former Xenomics shareholders and certain principal
shareholders.
o entered into a Technology Acquisition Agreement with the
former Xenomics shareholders under which we granted an option
to the former Xenomics holders to acquire Xenomics technology
if we fail to apply at least 50% of the net proceeds of
financing we raise to the development of Xenomics technology
during the period ending July 1, 2006 in exchange for all of
our shares and share equivalents held by the former Xenomics
holders at the time such option is exercised.
8
Results of Operations
---------------------
Three Months Ended July 31, 2004 and July 31, 2003.
---------------------------------------------------
We had no revenues during the three months ended July 31, 2004 and 2003 because
we do not have any commercial products and we do not expect to have any for the
foreseeable future.
Operating expenses increased to $92,953 during the three months ended July 31,
2004 from $559 for the same period in 2003. This increase was primarily the
result of the Exchange with Xenomics discussed elsewhere in this report. The
results of operations of Xenomics for the period July 2, 2004 through July 31,
2004 are included in the consolidated statement of operations for the three
months ended July 31, 2004, as well as the consolidated balance sheet as of July
31, 2004.
Net loss for the three months ended July 31, 2004 was $92,953 compared to $559
for the same period in 2003. The increase in the net loss is the result of
higher operating expenses as described above.
Six Months Ended July 31, 2004 and July 31, 2003.
-------------------------------------------------
We had no revenues during the six months ended July 31, 2004 and 2003 because we
do not have any commercial products and we do not expect to have any for the
foreseeable future.
Operating expenses increased to $95,773 during the three months ended July 31,
2004 from $424 for the same period in 2003. This increase was primarily the
result of the Exchange with Xenomics discussed elsewhere in this report. The
results of operations of Xenomics for the period July 2, 2004 through July 31,
2004 are included in the consolidated statement of operations for the three
months ended July 31, 2004, as well as the consolidated balance sheet as of July
31, 2004.
Net loss for the three months ended July 31, 2004 was $95,773 compared to $424
for the same period in 2003. The increase in the net loss is the result of
higher operating expenses as described above.
Liquidity and Capital Resources.
--------------------------------
As of July 31, 2004 we had $1,505,095 in cash and cash equivalents. On June 24,
2004, we sold and issued in a private placement to accredited investors an
aggregate 2,645,210 shares of common stock at an issue price of $0.95 per share
for aggregate gross proceeds of $2,512,859.
On September 15, 2004 we entered into a seven year lease for our corporate
headquarters in New York City comprising 1,963 square feet with an approximate
fixed rent of $75,000 per year through 2011. On July 7, 2004, we entered into a
two year lease for our laboratory in New Jersey comprising 3,698 square feet
with an approximate fixed rent of $7,400 per month through 2006.
Our working capital requirements will depend upon numerous factors including but
not limited to the nature, cost and timing of: product development; pre-clinical
and clinical testing; obtaining regulatory approvals; technological advances and
our ability to establish collaborative arrangements with research organizations
and individuals needed to commercialize our products. Our capital resources will
be focused primarily on the clinical development and regulatory approval of
Tr-NA technology. We expect that our existing capital resources will be
sufficient to fund our operations for at least the next 12 months. We will be
required to raise additional capital to complete the development and
commercialization of our current product candidates.
9
Item 3. Controls and Procedures
Our President and Principal Financial Officer, based on the evaluation of our
disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)
of the Securities Exchange Act of 1934, as amended) required by paragraph (b) of
Rule 13a-15 or Rule 15d-15, as of the end of the period covered by this report,
have concluded that our disclosure controls and procedures were effective to
ensure the timely collection, evaluation and disclosure of information relating
to our company that would potentially be subject to disclosure under the
Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder.
During the three months ended July 31, 2004, there were no changes in our
internal control over financial reporting identified in connection with the
evaluation required by paragraph (d) of Rule 13a-15 or Rule 15d-15 that has
materially affected, or is reasonably likely to materially affect, our internal
control over financial reporting.
10
PART II. OTHER INFORMATION
Item 2. Changes in Securities and Use of Proceeds
On June 24, 2004, we sold and issued in a private placement to accredited
investors an aggregate 2,645,210 shares of common stock at an issue price of
$0.95 per share for aggregate gross proceeds of $2,512,950. The issuance of
shares was done in accordance with Regulation D under the Securities Act of
1933, as amended. In connection therewith, a filing on Form D with the
Securities and Exchange Commission was made on June 30, 2004. We intend to use
the net proceeds from the sale of these shares for working capital and to
further the clinical development of our Tr-NA technology.
11
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits
31.1 Certification of President required under Rule
13a-14(a)/15d-14(a) under the Exchange Act.
31.2 Certification of Principal Financial Officer required
under Rule 13a-14(a)/15d-14(a) under the Exchange
Act.
32.1 Certification of President pursuant to 18 U.S.C
Section 1350, as adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002.
32.2 Certification of Principal Financial Officer pursuant
to 18 U.S.C Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
(b) Reports on Form 8-K.
On June 2, 2004, we filed a Form 8-K announcing that Xenomics, Inc.
(formerly Used Kar Parts, Inc.), a Florida corporation, Xenomics, a
California corporation, and certain individuals entered into a
Securities Exchange Agreement pursuant to which Xenomics, Inc. agreed
to purchase all of the outstanding shares of common stock of Xenomics
which is owned by the shareholders aggregating 3,807,055 shares in
exchange for 2,258,001 shares of common stock of Xenomics, Inc.
On July 19, 2004, we filed a Form 8-K announcing the closing of our
acquisition of Xenomics and completion of a private placement of
2,645,210 shares of our common stock for aggregate proceeds of
$2,512,950.
On July 28, 2004, we filed a Form 8-K/A which amended our Form 8-K
filed on July 19, 2004 by including a Descriptive Memorandum of the
company and its acquisition of Xenomics as an exhibit.
12
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
XENOMICS, INC.
(Registrant)
Date: September 20, 2004 By: /s/ Samuil Umansky
--------------------------
Samuil Umansky
President
Date: September 20, 2004 By: /s/ Christoph Bruening
--------------------------
Christoph Bruening
Treasurer
13